Newly-identified protein may contribute to colon cancer development
the ONA take:
A newly-identified pathway may contribute to the development of colon cancer, according to a study published in PLoS Genetics.
Researchers led by Anil Rustgi, MD, of the Perelman School of Medicine at the University of Pennsylvania conducted a follow-up to a 2013 study that identified the LIN28B protein as a contributor of cancerous growth in intestinal cells through suppression of Let-7 molecules.
In the new study, the researchers created transgenic mice that produced no Let-7 miRNAs in order to better understand their function in preventing cancer.
They found that adenomas adenomatous polyps, as well as adenocarcinomas that resembled human colon tumors, had formed in the intestines of all these mice without Let-7 by mid-adulthood.
Upon analyses of the tumors, they were able to identify a protein called Hmga2 as a major factor in their development. They were able to conclude that within the intestinal lining of the mice without Let-7, Hmga2 gene expression was unusually high.
In order to check the relevance of these findings, the researchers also examined several hundred human colorectal cancer samples and found lower-than-normal Let-7 miRNA as well as higher-than-normal HMGA2 (the human version of the mouse Hmga2 protein) expression.
A newly-identified pathway may contribute to the development of colon cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|